Indeed, ARID1A‐mutant ovarian cancer cell lines OVISE and TOV21G have displayed sensitivity to EZH2 inhibition, and in wild‐type ARID1A cells, its knockdown confers EZH2 sensitivity.55, 59. This evidence concerns the gene EZH2 and ovarian carcinoma.